Table 3.
SNP polymorphisms in patients with bladder cancer and control group
| SNPgenotype/allele | Bladder cancer patients (n=60) | Healthy control (n=60) | X2 | OR (95% CI) | p |
|---|---|---|---|---|---|
| CYP1A1: c.*1189T > C | |||||
| TT | 30 (50.0%) | 47 (78.3%) | 10.474 | Reference | Reference |
| TC | 29 (48.3%) | 12 (20.0%) | 10.707 | 3.742 (1.664 – 8.414 | 0.001 |
| CC | 1 (1.7%) | 1 (1.7%) | 0.000 | 1.000 (0.061–16.366) | 1.000 |
| T | 89 (74.2%) | 106 (88.3%) | 7.904 | Reference | Reference |
| C | 31 (25.8%) | 14 (11.4%) | 7.904 | 2.637 (1.321 – 5.264) | 0.005 |
|
| |||||
| GSTP1: c.313A > G | |||||
| AA | 38 (63.3%) | 34 (56.7%) | 0.556 | Reference | Reference |
| AG | 19 (31.7%) | 21 (35.0%) | 0.150 | 0.861 (0.403 – 1.840) | 0.699 |
| GG | 3 (5.0%) | 5 (8.3%) | 0.536 | 0.579 (0.132 – 2.540) | 0.464 |
| A | 95 (79.2%) | 89 (74.2%) | 0.839 | Reference | Reference |
| G | 25 (20.8%) | 31 (25.8%) | 0.839 | 0.756 (0.414 – 1.378) | 0.360 |
X2: Chi-square; OR: odds ratio; CI: confidence interval; SNP: single nucleotide polymorphism